医药魔方 / 最新资讯 / 正文

首发 | 益方生物完成7000万美元C轮融资:加快推进差异化创新药项目至临床后期

医药魔方 医药魔方 来源:医药魔方
2019-03-12
创新药
原文

2019年3月12日,益方生物(InventisBio)宣布完成7000万美元(约5亿元人民币)的C轮融资。此轮融资由尚珹投资、招银国际共同领投,浦东科创、礼来亚洲基金和奥博亚洲资本跟投,主要用于益方生物临床管线产品的推进以及数个临床前“first-in-class”在研创新药的开发。

 

益方生物位于上海张江药谷,专注于肿瘤、代谢等重大疾病的创新药开发,同时也在积极开发用于肿瘤免疫联合治疗的其他创新药。益方生物在美国和中国临床开发方面拥有丰富的注册、法规和运营经验,在临床试验执行上展现出高效率,不到一年即完成首个临床I期。益方生物在成立之初获得了美丽境界资本的天使投资,2016年获得礼来亚洲基金领投的A轮融资,并于2017年获得由奥博亚洲领投,礼来亚洲基金跟投的B轮融资,合计融资超过2亿元人民币。



益方生物的核心产品之一是治疗肺癌的EGFR T790M抑制剂D-0316,在Ⅰ期临床试验中显示出了好于同类上市产品的安全性且具有相似的疗效。正是由于出色的竞争力,贝达药业与益方生物在2018年12月达成协议,以2.3亿元的首付款以及后续研发里程金获得了D-0316在中国(包含香港、台湾)的独家开发权。如果D-0316成功上市销售,贝达药业还需按照约定条约向益方生物支付销售里程金和销售分成。

 

D-0316针对非小细胞肺癌的II期临床研究信息2月27日刚刚在国家临床试验登记平台上公示,纳入的是既往接受过一代或二代EGFR-TKI耐药后产生T790M突变的局部晚期或转移性非小细胞肺癌患者,计划入组300人。目前还没有国产T790M抑制剂获批上市,原研药奥希替尼2018年全球销售额达到18.6亿美元,其中中国市场的销售收入超过20亿元。贝达药业在肺癌产品的市场推广及销售上处于国内领先地位,这对D-0316将来上市后的商业化将会是很大的优势。


除了D-0316之外,益方生物的在研产品还有用于治疗乳腺癌的选择性雌激素受体降解剂(SERD)D-0502和用于治疗痛风的尿酸转运蛋白1(URAT1)抑制剂D-0120。

 

D-0502相比其他选择性雌激素受体降解剂在药代动力学方面进行了大幅优化,不仅提高了药效,还极大改善了安全性。益方生物曾在2018年3月召开的美国癌症研究协会年会(AACR)上公布过D-0502的临床前数据,在2018年底召开的圣安东尼奥乳腺癌的大会(SABC)大会上以壁报形式公布过D-0502单用以及与CDK4/6抑制剂Palbociclib联用对晚期或转移性ER+/HER2-的乳腺癌I期研究计划和初步结果。

 

在临床前的产品管线方面,益方生物也正在布局一些肿瘤免疫,肿瘤靶向药,和代谢病相关的First-in-Class或Best-in-Class的新药研发。


益方生物董事长王耀林

 

益方生物董事长和首席执行官王耀林博士表示: “这次的融资将帮助我们进一步开发具有自主知识产权的创新药,开展国际多中心临床试验,让各国的患者从益方生物开发的新药中受益;同时也将有助于我们团队的扩展,希望有更多优秀研发人才加入益方生物的创业团队中来。我们很高兴获得了尚珹投资和招银国际这样知名基金和投资人的支持。前两轮的领投方礼来亚洲基金与奥博亚洲资本在这轮融资中的进一步注资,也显示了我们的战略投资者对益方生物团队和公司临床产品在未来全球医药市场上的信心。”

 

尚珹投资合伙人和医疗投资联席主管裘育敏表示:“益方生物作为创新药研发企业,设计思路清晰,注重创新性与成药性的平衡,充分发挥创始团队在小分子化学结构方面的技术积累,结合临床经验,针对机理确认的药物靶点做具有显著临床价值的创新。经过多年的积累,打造了独特的技术平台和优质的研发管线。医药健康是尚珹投资的重点投资领域之一,益方生物技术门槛高、平台延展性大的特点符合尚珹的投资理念。尚珹投资很荣幸助力益方生物,推进创新品种的研发与临床试验,造福患者。”

 

关于尚珹投资

尚珹投资是一家专注中国市场的私募股权投资基金,关注创新驱动的成长型投资机会,主要投资于科技与创新、医疗医药健康服务业。

 

关于招银国际

招银国际金融有限公司(简称“招银国际”)是一家立足香港、深植内地、面向全球的全方位、专业化综合金融服务机构。作为招商银行股份有限公司的全资附属机构,招银国际及其子公司凭借集团境内外协同和联动的优势,依托母行的雄厚实力和卓著的社会声誉,积极实施多元化经营战略,全面布局了企业融资、资产管理、财富管理、股票、结构融资等业务版块。

 

关于浦东科创

浦东科创集团主要从事创业投资、基金管理、科技担保、科技贷款、科技孵化等科技金融业务,重点关注自主创新的高新技术企业,涵盖集成电路、生物医药、高端装备、互联网/新媒体等国家政策重点扶持的行业领域。


益方生物官网:http://doc.pharmcube.com/imagebc08210757874eb498e39e27ca8fc185

机器翻译

On March 12, 2019, InventisBio announced the completion of a $70 million (about 500 million yuan) round of financing.This round of financing is invested by shang shang.Zhaoyin international co-leader, pudong kechuang.Lilly Asia Fund and Aobo Asia Capital are mainly used for the promotion of clinical pipeline products of Yifang Biology and the development of several preclinical "first-in-class" innovative drugs.

Yifang Biology is located in Zhangjiang Pharmaceutical Valley in Shanghai and focuses on cancer.The development of innovative drugs for major diseases such as metabolism is also actively developing other innovative drugs for cancer immune combination therapy.Yifang Biological has rich registration in clinical development in the United States and China.Regulatory and operational experience, showing high efficiency in the conduct of clinical trials, with the first clinical phase I completed in less than a year.At the beginning of its establishment, Yifang Biology obtained the angel investment of Beautiful State Capital. In 2016, it obtained the round A financing led by Lilly Asia Fund, and in 2017, it obtained the round B financing led by Aobo Asia and invested by Lilly Asia Fund, with a total financing of more than 200 million yuan.

One of the core products of Yifang Biological Co., Ltd., EGFR T790M inhibitor D-0316 for lung cancer, showed better safety and similar efficacy than similar marketed products in phase I clinical trial.It was due to its outstanding competitiveness that Betta and Yifang Biological reached an agreement in December 2018 to obtain D-0316 for a first payment of 230 million yuan and subsequent R & D mileage in China (including Hong Kong.Taiwan) for exclusive development rights.If D-0316 is successfully marketed, Betta Pharmaceuticals will also be required to pay sales mileage and sales share to Yifang Biology in accordance with the agreed treaty.

D-0316 Phase II clinical study information for non-small cell lung cancer was just announced on the national clinical trial registration platform on February 27, including patients with locally advanced or metastatic non-small cell lung cancer with T790M mutation after previous treatment with first- or second-generation EGFR-TKIs. It is planned to enroll 300 patients.At present, there is no domestic T790M inhibitor approved for marketing. The global sales of originator Osimertinib in 2018 reached 1.86 billion US dollars, of which the sales revenue in China exceeded 2 billion yuan.Betta Pharmaceutical Co., Ltd. is a leader in the marketing and sales of lung cancer products, which will be a great advantage for the commercialization of D-0316 in the future.

In addition to D-0316, Yifang Biological's products under development include selective estrogen receptor degrader (SERD) D-0502 for the treatment of breast cancer and uric acid transporter 1 (URAT1) inhibitor D-0120 for the treatment of gout.

D-0502 has been substantially optimized compared to other selective estrogen receptor degraders in terms of pharmacokinetics, improving not only efficacy but also safety.The preclinical data of D-0502 was published by Yifang Biological at the American Association for Cancer Research Annual Meeting (AACR) in March 2018, and the phase I study plan and preliminary results of D-0502 alone and in combination with CDK4/6 inhibitor Palbociclib for advanced or metastatic ER +/HER2- breast cancer were presented in a poster at the San Antonio Breast Cancer Conference (SABC) in late 2018.

In the preclinical product pipeline, Yifang Biology is also laying out a number of cancer immunity, tumor-targeted drugs, and metabolic disease-related First-in-Class or Best-in-Class drug development.

Yifang Biology Chairman Wang Yaolin

Dr. Wang Yaolin, Chairman and CEO of Yifang Biology, said: "This financing will help us to further develop innovative drugs with independent intellectual property rights and carry out international multicenter clinical trials so that patients in various countries can benefit from new drugs developed by Yifang Biology.At the same time, it will also help our team to expand and hope that more outstanding R & D talents will join the entrepreneurial team of Yifang Biology.We are pleased to receive support from well-known funds and investors such as Shang Kang Investment and Zhaobin International.The further capital injection of Lilly Asia Fund, the lead investor in the first two rounds of financing, and Aobo Asia Capital in this round of financing also shows the confidence of our strategic investors in the future global pharmaceutical market of the Yifang Biology Team and the company's clinical products.

"As an innovative drug R & D enterprise, Yifang Biology has clear design ideas, focuses on the balance between innovation and druggability, gives full play to the technical accumulation of the founding team in terms of small molecule chemical structure, and combines clinical experience to make innovations with significant clinical value for mechanistically confirmed drug targets," said Ju Yumin, partner of Shangshang Investment and co-head of medical investment.After years of accumulation, built a unique technology platform and high-quality R & D pipeline.Medicine and health is one of the key investment areas of Shangshang.The large extensibility of the platform accords with the investment idea of Shangshang.It is a great honor for Shangshang Investment to help Yifang Biology and promote the R & D and clinical trials of innovative varieties for the benefit of patients.

About Sangkang Investment

Shangshang Investment is a private equity fund focused on the Chinese market, focusing on innovation-driven growth investment opportunities, mainly in technology and innovation.Medical and pharmaceutical health services.

About VB International

(p) Zhaobin International Finance Co., Ltd. ("Zhaobin International") is a Hong Kong-based company.Deep in the mainland.The whole world.Specialized integrated financial services organization.As a wholly owned subsidiary of China Merchants Bank Co., Ltd., ZhaoBin International and its subsidiaries rely on the advantages of coordination and linkage at home and abroad, relying on the strong strength and outstanding social reputation of the parent bank, actively implementing diversified business strategies, and comprehensively distributing enterprise financing.Asset Management.Wealth management.Stocks.Structured finance and other business sections.

About Pudong Kechuang

Pudong Kechuang Group is mainly engaged in venture capital investment.Fund management.Technology guarantee.Technology loans.Science and technology incubation and other science and technology financial business, focusing on independent innovation of high-tech enterprises, including integrated circuits.Biomedicine.High-end equipment.Internet/new media and other industries supported by national policies.

Yifang Biology Official Website:http://doc.pharmcube.com/imagebc08210757874eb498e39e27ca8fc185

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号